YourLawyer.com 1-800-LAW-INFO (1-800-529-4636)

Alzheimer Drugs May Increase Death Risks

Oct 19, 2005 | www.newsinferno.com

Popular antipsychotic drugs may increase the risk of death when given to people with dementia, according to an analysis done by researchers at the University of California.

The research team analyzed 15 trials involving about 5,000 patients to determine if there was a correlation between the use of the antipsychotic drugs and an increased risk for death.  During the trails 3,353 patients took the antipsychotics and 1,757 were given placebos.  The researchers found that the risk of death rose from 2 percent to 3 percent for patients taking the antipsychotic drugs.

The research team, led by Lon Schneider, professor of psychiatry, neurology, and gerontology in the Keck School at USC, studied the correlation between aripiprazole (Abilify), olanzapine (Zyprexa), quetiapine (Seroquel), and risperidone (Risperdal) and an increased risk for death.  There were 188 deaths associated with the antipsychotic drugs compared to 40 deaths associated with the placebos.

When the specific drugs were examined individually, there was no significant difference between the risks conferred by one drug over another.  The researchers noted that the differences “could not have been recognized by examining any individual trial.  The events were too sparse and the trials too small to be able to meaningfully assess for a dose response that might make attribution more compelling.”

According to the Washington Post, about a third of the 4 million to 5 million Americans with degenerative brain disorder are given antipsychotic drugs.  The drugs are approved for the treatment of psychosis in adults, but have not been specifically approved for use among elderly patients with dementia.

Mr. Schneider and his team found that most of the deaths came from cardiac problems or respiratory disorders.  He said that the drugs might increase the risk because they sedate patients and confine them to bed for longer periods, making them more likely to develop infections.

The analysis appears in the October 19 issue of the Journal of the American Medical Association.
Atypical Antipsychotic Drugs
* Denotes required field.

Title

* First Name

* Last Name

* Email Address

* Phone Number

Cell Phone Number

Office Phone Number

Street Address

Apartment/Suite

City

State

Zip Code

Please provide the best method and times to contact you:

Date of birth of person injured
(mm-dd-yyyy):

Date you started taking the drug (mm-yyyy):

Date you stopped taking the drug (mm-yyyy):

Which atypical antipsychotic drug(s) did the patient take?

What condition was this medication prescribed to treat?

Please describe any side effects:

Other Info:

No Yes, I agree to the Parker Waichman Alonso LLP disclaimers.Click here to review all.

Yes, I would like to receive the Parker Waichman Alonso LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Bad Med
 
 

News Feeds

WE ALSO OFFER OUR FIRM NEWS AS RSS/XML FEEDS.
LEARN MORE ABOUT RSS

Home | Defective Drugs | Medical Devices | Toxic Substances | Accidents | Product Liability | Malpractice | Diseases
Nursing Home Negligence | Food Poisoning | Other Topics | Contact
Statement of Clients' Rights | Site Map | ReNu with MoistureLoc | Vioxx | Mesothelioma | Permax | Dostinex | Composix Kugel Mesh X Large Patch
Ortho Evra | Fosamax | Personal Injury Lawyer | Fusarium Keratitis | Stevens Johnson Syndrome

© 2002-2008 YourLawyer.com. All Rights Reserved.

Please note that you are not considered a client until you have signed a retainer agreement and your case has been accepted by us.
Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Attorney Advertising

Parker Waichman Personal Injury News